Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
Date:11/9/2010

er were presented at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society. The data presented showed that lorcaserin reduces energy intake and appetite, and causes weight loss without stimulating energy expenditure.
  • The FDA completed the Pre-Approval Inspection of Arena's drug product manufacturing facility in Switzerland and classified the inspection as No Action Indicated.
  • Results from Arena's two-year, pivotal Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial were published in the July 15, 2010, issue of the New England Journal of Medicine. The data presented in the article show that lorcaserin used in conjunction with behavioral modification caused significantly greater weight loss and improved maintenance of weight loss compared to placebo. The data also indicated that lorcaserin improved values for biomarkers that may be predictive of future cardiovascular events, including lipid levels, insulin resistance, levels of inflammatory markers and blood pressure.
  • Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, entered into a marketing and supply agreement with Eisai Inc. for the commercialization of lorcaserin in the United States following FDA approval of the NDA for lorcaserin. Under the terms of the agreement, Arena received a non-refundable, upfront payment of $50.0 million from Eisai.

  • Other

  • Announced that following the completion of a Phase 1 clinical trial program for APD597, Ortho-McNeil-Janssen Pharmaceuticals, Inc., decided not to advance APD597 and notified Arena that it is terminating their collaboration, effective December 28, 2010. APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, which, along with other compounds and intellectual property, will revert to Arena upon termination of the collaboration. The Phase 1 program provided evidence for incretin stimulation (GLP-1, GIP and PYY) and reducti
    '/>"/>

  • SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
    2. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
    3. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
    4. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
    5. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
    6. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
    7. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
    8. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
    9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
    10. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
    11. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
    (Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
    (Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
    Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
    (Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. , Titled "Evidence-Conformant ... developed at UH to enhance care for adult cancer ... for high health care utilization. , "We ...
    (Date:7/10/2014)... illness and even death are likely to result if ... Now, however, a team of researchers based at The ... order of infection, the bacteria Streptococcus pneumoniae ... case of the flu. , The researchers discovered ... a bacterial virulence factor, might protect macrophagesa type of ...
    (Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
    (Date:7/9/2014)... 2014 -- The World Health Organization recommends that youth ... to vigorous physical activity (MVPA) each day. Studies ... during school hours. Therefore, it stands to reason ... MVPA. In a new study scheduled for publication ... that time spent outdoors after school was positively associated ...
    (Date:7/9/2014)... had an aneurysm, she figured an invasive brain surgery and ... said Wakulich, who is 56 years old and lives in ... Then I met Dr. Bernard Bendok who told me about ... was something I didn,t even know was an option." , ... to evaluate the safety and effectiveness of the Microvention Inc. ...
    Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:New type of stent could help some brain aneurysm patients 2
    ... Department of Defense (DOD) Breast Cancer Research Program (BCRP) ... Programs has awarded Silvia Formenti, MD, the Sandra and ... Radiation Oncology a $4.5 million Multi-Team Award to conduct ... offers tremendous promise for new therapeutic options for patients ...
    ... News) -- Certain gene mutations influence how likely people ... counter to experience, say researchers at Brown University. ... without gene mutations that affect the activity of the ... the prefrontal cortex and the striatum. The prefrontal ...
    ... TUESDAY, April 19 (HealthDay News) -- Nearly one-third of ... experience depression after the injury, a new study finds. ... existing research on blunt force trauma head injuries suffered ... "Any patient who has a traumatic brain injury ...
    ... release is available in German . ... consequences: Around first grade, the children start experiencing vision ... complete blindness. This is the first indication of a ... experience hallucinations, epileptic seizures, dementia and, finally, failure of ...
    ... glioma from chemoradiation may result in improved patient survival, ... Kimmel Cancer Center at Jefferson suggests. These ... the British Journal of Cancer . The ... such as fatigue and loss of short-term memory, that ...
    ... implants appear to be associated with a rare form of lymphoma, ... is caused by implants or to suggest an underlying mechanism for ... from the RAND Corporation. The study, published online by ... the disease takes a slow course and can be controlled by ...
    Cached Medicine News:Health News:NYU Langone Medical Center awarded $4.5 million for breast cancer research 2Health News:Depression Common After Brain Injury 2Health News:Hope for children with rare genetic defect 2Health News:Hope for children with rare genetic defect 3Health News:Minimizing side effects from chemoradiation could help brain cancer patients live longer 2Health News:Study confirms link between breast implants and rare form of cancer 2Health News:Study confirms link between breast implants and rare form of cancer 3
    Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
    Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....
    ... RTVue is an ultra-high speed, high resolution ... for retina imaging and analysis. ... Fourier-Domain Optical Coherence technology just emerging from ... The ultra-high speed and high ...
    The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
    Medicine Products: